Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreakAntivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infectionRitonavir-bosted lopinavir is effective against SARS-CoV-2 in vitroSequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patientRitonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection
Source: Journal of Infection - Category: Infectious Diseases Authors: Elise Klement-Frutos, Sonia Burrel, Gilles Peytavin, St éphane Marot, Minh P. Lê, Nagisa Godefroy, Vincent Calvez, Anne-Geneviève Marcelin, Eric Caumes, Valérie Pourcher, David Boutolleau Tags: Virology and pharmacology of LPV/r in SARS-CoV-2-infected patient Source Type: research
More News: COVID-19 | Drugs & Pharmacology | Infectious Diseases | Kaletra | Norvir | SARS | Virology